{"filing":{"accession_number":"0001140361-26-030497","cik":"0001472091","ticker":"PDSB","company_name":"PDS Biotechnology Corp","form":"8-K","filing_date":"2026-07-31","report_date":"2026-07-30","primary_document":"ef20079199_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126030497/ef20079199_8k.htm"},"events":[{"id":22401,"run_id":20264,"accession_number":"0001140361-26-030497","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"PDS Biotechnology received a deficiency letter from Nasdaq on July 30, 2026, notifying the company that its closing bid price has fallen below the $1.00 minimum required under Nasdaq Listing Rule 5550(a)(2). The company has been granted a 180-day compliance period (until January 26, 2027) to regain compliance, with the explicit warning that failure to do so will result in delisting. This is a classic delisting-risk disclosure under Item 3.01.","company_name":"PDS Biotechnology Corp","ticker":"PDSB","filing_date":"2026-07-31","form":"8-K","submitted_at":null,"items":[{"id":22329,"accession_number":"0001140361-26-030497","item_number":"3.01","item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"PDS Biotechnology received a deficiency letter from Nasdaq on July 30, 2026, notifying the company that its closing bid price has fallen below the $1.00 minimum required under Nasdaq Listing Rule 5550(a)(2). The company has been granted a 180-day compliance period (until January 26, 2027) to regain compliance, with the explicit warning that failure to do so will result in delisting. This is a classic delisting-risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T00:12:55.876927+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22329,"accession_number":"0001140361-26-030497","item_number":"3.01","item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"PDS Biotechnology received a deficiency letter from Nasdaq on July 30, 2026, notifying the company that its closing bid price has fallen below the $1.00 minimum required under Nasdaq Listing Rule 5550(a)(2). The company has been granted a 180-day compliance period (until January 26, 2027) to regain compliance, with the explicit warning that failure to do so will result in delisting. This is a classic delisting-risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T00:12:55.876927+00:00","company_name":"PDS Biotechnology Corp","ticker":"PDSB","filing_date":"2026-07-31"}]}